A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Alvotech stock. As of the latest transaction made, Citadel Advisors LLC holds 21,249 shares of ALVO stock, worth $266,887. This represents 0.0% of its overall portfolio holdings.

Number of Shares
21,249
Holding current value
$266,887
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.76 - $12.99 $228,639 - $276,024
21,249 New
21,249 $252,000
Q4 2023

Feb 14, 2024

BUY
$8.55 - $11.48 $143,152 - $192,209
16,743 New
16,743 $192,000

Others Institutions Holding ALVO

About Alvotech


  • Ticker ALVO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 248,650,000
  • Market Cap $3.12B
  • Description
  • Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...
More about ALVO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.